<i>Wisteria floribunda</i> agglutinin‐positive human Mac‐2 binding protein predicts the risk of <scp>HBV</scp>‐related liver cancer development

Heo, June Seok; Kim, Seung Up; Park, Jun Yong; Kim, Do Young; Han, Kwang‐Hyub; Ahn, Sang Hoon; Kim, Hyun Sook

doi:10.1111/liv.13341

Cited by 39 publications

(49 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effect of underlying liver disease on M2BPGi performance should also be evaluated in greater depth. M2BPGi has been shown to be predictive of HCC in East Asian cohorts with HCV, HBV, and NAFLD but with different optimal threshold values in each . We found that there was a significant interaction between underlying liver disease and M2BPGi in our cohort, even after taking cirrhosis into account.…”

Section: Discussionmentioning

confidence: 58%

“…It is possible that alternative lectins could improve the test’s performance in non‐Japanese HCV populations. For HBV, M2BPGi has been successfully used in Korean and Chinese populations in addition to Japanese populations, demonstrating that the test is robust to some changes in patient population …”

Section: Discussionmentioning

confidence: 99%

“…In addition to HCV, the Mac‐2 binding protein glycosylation isomer (M2BPGi) has been studied as a marker for fibrosis in chronic hepatitis B virus (HBV) infection, nonalcoholic fatty liver disease (NAFLD), and primary biliary cirrhosis, among others . It has also been evaluated as a biomarker for HCC in HBV, HCV, and NAFLD, with favorable results …”

mentioning

confidence: 99%

See 2 more Smart Citations

Mac‐2 Binding Protein Glycosylation Isomer as a Hepatocellular Carcinoma Marker in Patients With Chronic Hepatitis B or C Infection

Jun¹,

Hsu

Ogawa³

et al. 2019

Hepatol Commun

View full text Add to dashboard Cite

Mac‐2 binding protein glycosylation isomer (M2BPGi) is a novel glycoprotein biomarker that correlates with liver fibrosis. It has been investigated in East Asian populations as a hepatocellular carcinoma (HCC) biomarker. We assessed M2BPGi as an HCC biomarker in an ethnically diverse cohort of patients with chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection. We enrolled 947 treatment‐naive patients mono‐infected with HBV or HCV without HCC at baseline. Biomarker levels were measured from baseline sera and correlated with longitudinal clinical data. The primary outcome was HCC occurrence during long‐term follow‐up. Median M2BPGi was significantly higher among patients with cirrhosis (2.67 versus 0.80; P < 0.001) and patients who developed HCC (3.22 versus 1.16; P < 0.001). The area under the receiver operating characteristic (AUROC) for M2BPGi and alpha‐fetoprotein (AFP) was similar overall (0.77 versus 0.72; P = 0.15), but M2BPGi outperformed AFP among patients with HBV (0.84 versus 0.75; P = 0.02). M2BPGi performed poorly among patients with HCV (AUROC, 0.51). M2BPGi was an independent predictor of HCC among patients with HBV but not among patients with HCV. M2BPGi performed better in patient subgroups with a lower prevalence of cirrhosis. Conclusion: In our HBV cohort, M2BPGi was more effective than AFP in predicting HCC and was an independent predictor of HCC. However, M2BPGi had limited predictive value in our HCV cohort, likely due to a high cirrhosis burden in this cohort. Further studies are needed to evaluate M2BPGi as an HCC biomarker in broader patient populations with more diverse disease etiology, non‐Asian ethnicity, and more advanced fibrosis.

show abstract

Section: Discussionmentioning

confidence: 58%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Mac‐2 Binding Protein Glycosylation Isomer as a Hepatocellular Carcinoma Marker in Patients With Chronic Hepatitis B or C Infection

Jun¹,

Hsu

Ogawa³

et al. 2019

Hepatol Commun

View full text Add to dashboard Cite

show abstract

“…Furthermore, glycan analysis of M2BPGi in patients with chronic hepatitis C should be performed similarly to that for AFP‐L3 . In addition to their utility as markers of fibrosis, serum levels of M2BPGi were found to be useful for the prediction of HCC development . Similar phenomena have been observed for other glyco‐biomarkers, such as fucosylated haptoglobin, suggesting that aberrant glycan alteration occurs in the early stages of hepatocarcinogenesis, and that such alterations might be useful biomarkers for diagnosis.…”

Section: Glyco‐biomarkers For Liver Diseasesmentioning

confidence: 71%

Functional glycomics: Application to medical science and hepatology

Miyoshi

Kamada

Suzuki

2019

Hepatology Research

View full text Add to dashboard Cite

Glycomics refers to the comprehensive analysis of glycans. Recent progress in glycotechnology enables the determination of a variety of biological functions of glycans. Among different glycosylation patterns, certain types of aberrant glycosylation are linked to cancer and/or inflammation, and thus have biological importance. Glycotechnology has been applied to many fields of medical science, including hepatology. In particular, dramatic changes in glycosylation are observed in the progression of liver diseases. As the liver produces so many serum glycoproteins, changes in glycosylation of these proteins might provide useful disease biomarkers. Furthermore, many patients with genetic diseases of glycosylation who have liver dysfunction have been found as a result from whole genome sequencing, and various kinds of glycotherapy have been developed, especially in immunotherapy. In this review, we describe our basic knowledge of glycobiology and discuss the application of these data to medical science, especially hepatology.

show abstract

“…In the recent years, M2BPGi has emerged as a novel biomarker that correlates well with hepatic fibrosis in patients with chronic liver diseases . Recent literature also suggests that M2BPGi may correlate with hepatocellular carcinoma (HCC) development in patients with chronic viral hepatitis, but most have been conducted in patients with chronic hepatitis C (CHC) or untreated chronic hepatitis B (CHB) without serial measurements …”

Section: Introductionmentioning

confidence: 99%

Serum M2BPGi level and risk of hepatocellular carcinoma after oral anti‐viral therapy in patients with chronic hepatitis B

Hsu

Jun

Huang

et al. 2018

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Summary Background Mac‐2 binding protein glycosylation isomer (M2BPGi) is an emerging biomarker for risk prediction of liver disease, but data remain sparse for patients with chronic hepatitis B (CHB) who are treated with nucleos(t)ide analogues (NA). Aim To clarify serial changes in M2BPGi and its association with subsequent hepatocellular carcinoma (HCC) development in NA‐treated CHB patients. Methods We enrolled 384 previously untreated CHB patients who received NAs. Among them, 195 had baseline cirrhosis (n = 142:48:5 for Child A:B:C). Sera were collected at NA initiation, and after 1 and 2 years. Serum M2BPGi levels were measured and expressed as cut‐off index (COI) at different time points. The association between M2BPGi and HCC was evaluated by the Cox proportional hazard model. Results The median M2BPGi levels significantly decreased from 1.68 COI at baseline, to 1.0 at year 1, and 0.88 at year 2. During median follow‐up of 72.7 months, HCC occurred in 37 patients, 36 of whom had cirrhosis. In patients with cirrhosis, baseline M2BPGi level was associated with HCC risk (adjusted hazard ratio, 1.07 per COI; 95% CI, 1.01‐1.14) on the multivariable Cox analysis, whereas levels at year 1 or 2 were not independently predictive. A risk score for HCC was developed using baseline M2BPGi, age and body mass index with c statistics of 0.77, 0.79 and 0.87 at 3, 5 and 10 years, respectively. Conclusions Serum M2BPGi level significantly decreases after NA treatment in CHB patients. Baseline level can be factored into the risk prediction of HCC in NA‐treated patients with cirrhosis.

show abstract

Wisteria floribunda agglutinin‐positive human Mac‐2 binding protein predicts the risk of HBV‐related liver cancer development

Abstract: WFA -M2BP level can independently predict HCC development. Further studies should investigate whether WFA -M2BP level could be incorporated into surveillance strategies for CHB patients.

Cited by 39 publications

References 38 publications

Mac‐2 Binding Protein Glycosylation Isomer as a Hepatocellular Carcinoma Marker in Patients With Chronic Hepatitis B or C Infection

Mac‐2 Binding Protein Glycosylation Isomer as a Hepatocellular Carcinoma Marker in Patients With Chronic Hepatitis B or C Infection

Functional glycomics: Application to medical science and hepatology

Serum M2BPGi level and risk of hepatocellular carcinoma after oral anti‐viral therapy in patients with chronic hepatitis B

Contact Info

Product

Resources

About